Tivanisiran, a novel siRNA for the treatment of dry eye disease

References

• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283.
   PubMed Web of Science ®Google Scholar
• Research in dry eye: report of the research subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):179–193.
   PubMed Web of Science ®Google Scholar
• Benítez-Del-Castillo J, Labetoulle M, Baudouin C, et al. Visual acuity and quality of life in dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2017;15(2):169–178.
   PubMed Web of Science ®Google Scholar
• Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334–365.
   PubMed Web of Science ®Google Scholar
• Chao W, Belmonte C, Benitez Del Castillo JM, et al. Report of the Inaugural Meeting of the TFOS i(2) = initiating innovation series: targeting the unmet need for dry eye treatment. Ocul Surf. 2016;14(2):264–316.
   PubMed Web of Science ®Google Scholar
• Colligris B, Alkozi HA, Pintor J. Recent developments on dry eye disease treatment compounds. Saudi J Ophthalmol. 2014;28(1):19–30.
   PubMedGoogle Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628.
   PubMed Web of Science ®Google Scholar
• Alio JL, Rodriguez AE, Ferreira-Oliveira R, et al. Treatment of dry eye disease with autologous platelet-rich plasma: a prospective, interventional, non-randomized study. Ophthalmol Ther. 2017;6(2):285–293.
   PubMed Web of Science ®Google Scholar
• Giannaccare G, Versura P, Buzzi M, et al. Blood derived eye drops for the treatment of cornea and ocular surface diseases. Transfus Apher Sci. 2017;56(4):595–604.
   PubMed Web of Science ®Google Scholar
• Marcet MM, Shtein RM, Bradley EA, et al. Safety and efficacy of lacrimal drainage system plugs for dry eye syndrome: a report by the American Academy of Ophthalmology. Ophthalmology. 2015;122(8):1681–1687.
   PubMed Web of Science ®Google Scholar
• Barabino S, Horwath-Winter J, Messmer EM, et al. The role of systemic and topical fatty acids for dry eye treatment. Prog Retin Eye Res. 2017;61:23–34.
   PubMed Web of Science ®Google Scholar
• Buckmaster F, Pearce EI. Effects of humidity on tests of tear production. Cornea. 2016;35(6):754–758.
   PubMed Web of Science ®Google Scholar
• Brinton M, Kossler AL, Patel ZM, et al. Enhanced tearing by electrical stimulation of the anterior ethmoid nerve. Invest Ophthalmol Vis Sci. 2017;58(4):2341–2348.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4): 287-296.
   PubMed Web of Science ®Google Scholar
• Sall K1, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 study group. Ophthalmology. 2000;107(4):631–639.
   PubMed Web of Science ®Google Scholar
• Stonecipher KG, Torkildsen GL, Ousler GW 3rd, et al. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. Clin Ophthalmol. 2016;10:887–895.
   PubMed Web of Science ®Google Scholar
• Godin MR, Gupta PK. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy. Clin Ophthalmol. 2017;11:951–957.
   PubMed Web of Science ®Google Scholar
• Leonardi A, DeFranchis G, Fregona IA, et al. Effects of cyclosporin A on human conjunctival fibroblasts. Arch Ophthalmol. 2001;119(10):1512–1517.
   PubMedGoogle Scholar
• Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized Phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423–2431.
   PubMed Web of Science ®Google Scholar
• Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis. 2014;6:37–42.
   PubMedGoogle Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475–483.
   PubMed Web of Science ®Google Scholar
• Takamura E, Tsubota K, Watanabe H, et al. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96(10):1310–1315.
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Oshiden K, Awamura S, et al. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology. 2013;120(6):1158–1165.
   PubMed Web of Science ®Google Scholar
• Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275–1285.
   PubMedGoogle Scholar
• Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877–884.
   PubMed Web of Science ®Google Scholar
• Jacobs DS. Diagnosis and treatment of ocular pain: the ophthalmologist’s perspective. Curr Ophthalmol Rep. 2017;5(4):271–275.
   PubMedGoogle Scholar
• Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457(7228):426–433.
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(7089):111–114.
   PubMed Web of Science ®Google Scholar
• Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther. 2006;13(4):644–670.
   PubMed Web of Science ®Google Scholar
• Bumcrot D, Manoharan M, Koteliansky V, et al. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2(12):711–719.
   PubMed Web of Science ®Google Scholar
• Bourinet E, Altier C, Hildebrand ME, et al. Calcium-permeable ion channels in pain signaling. Physiol Rev. 2014;94(1):81–140.
   PubMed Web of Science ®Google Scholar
• Pan Z, C.-A. JE, R PS. Transient receptor potential (TRP) channels in the eye. In: Rumelt S, editor. Advances in ophthalmology. InTech; 2012. p. 35–46.
   Google Scholar
• Okada Y, Reinach PS, Shirai K, et al. TRPV1 involvement in inflammatory tissue fibrosis in mice. Am J Pathol. 2011;178(6):2654–2664.
   PubMed Web of Science ®Google Scholar
• Pan Z, Wang Z, Yang H, et al. TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2011;52(1):485–493.
   PubMed Web of Science ®Google Scholar
• Gonzalez GG, Garcia de la Rubia P, Gallar J, et al. Reduction of capsaicin-induced ocular pain and neurogenic inflammation by calcium antagonists. Invest Ophthalmol Vis Sci. 1993;34(12):3329–3335.
   PubMed Web of Science ®Google Scholar
• Stein CA, Hansen JB, Lai J, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucl Acids Res. 2010;38(1):e3.
   PubMed Web of Science ®Google Scholar
• Bian Y, Zhou W, Zhao Y, et al. High-dose siRNAs upregulate mouse Eri-1 at both transcription and posttranscription levels. PLoS One. 2011;6(10):e26466.
   PubMed Web of Science ®Google Scholar
• Hong J, Qian Z, Shen S, et al. High doses of siRNAs induce eri-1 and adar-1 gene expression and reduce the efficiency of RNA interference in the mouse. Biochem J. 2005;390(Pt 3):675–679.
   PubMedGoogle Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–829.
   PubMed Web of Science ®Google Scholar
• Benitez-Del-Castillo JM, Moreno-Montañés J, Jiménez-Alfaro I, et al. Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. Invest Ophthalmol Vis Sci. 2016;57(14):6447–6454.
   PubMed Web of Science ®Google Scholar